Lucas Montarce

That's included in our guide.

Very strong volume growth that we expect to see that will more than offset that to get to that 25% that we have in our guide.

Yeah, that's very important.

As you mentioned, again, when you think about the volume growth and the volume opportunity, in particular starting with both obesity and type 2 diabetes, we have a large opportunity.

Both segments are really large, in particular in anti-bacterial medications.

We are talking about more than 100 million patients in the U.S.

that we can serve.

And then globally, there is another 900 million patients that we can serve as well.

Nowadays, we are serving...

low single digits.

So the penetration is low.

So there is a big opportunity to continue to drive that growth.

The fourth quarter, I mentioned that the market in the U.S.

grew 85%.

So there is a very big runway to continue to drive growth into the future.

That's reflected on our volume growth expectation for 2026.

So the impact is included in that guide that I talk about, again, the low to mid-teens in price erosion.

That's reflected in that price guide that we have for the year.

And the prices, as I mentioned, are public.

They're $2.45 for the government segment, and the public prices that we have indirect to patients, including the adjustment that we did for $50.